IP Library Granted Patent US 10,973,928
Granted Patent B2
US 10,973,928 · App. 16/045,043 · Granted Apr 13, 2021

Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor

Inventors: James M. Wilson (Philadelphia, PA); Guangping Gao (Westborough, MA); Mauricio R. Alvira (Philadelphia, PA); Luc H. Vandenberghe (Weston, MA)
Assignee: The Trustees of the University of Pennsylvania
A61K48/00C07K14/005C07K14/705C12N7/00C12N9/644C12N15/86C12Y304/21022C12N2750/14121C12N2750/14122C12N2750/14142C12N2750/14143C12N2750/14151C12N2830/008C12N2830/48C12N2830/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,928
App. No.
16/045,043
Granted
Apr 13, 2021
Kind
B2
Abstract

Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.

Claims (11)

1. A recombinant adeno-associated virus (rAAV) having an AAV capsid comprising vp1 proteins, vp2 proteins, and vp3 proteins, wherein the vp3 proteins have the amino acid sequence of amino acids 203 to 736 of SEQ ID NO: 123 (AAV9 capsid protein) with 1 to 26 amino acid modifications, and wherein the AAV capsid has packaged therein a minigene having AAV inverted terminal repeats and a heterologous gene operably linked to regulatory sequences which direct expression of the heterologous gene in a host cell.

2. The rAAV according to claim 1 , wherein the AAV vp3 capsid protein has an amino acid sequence which is at least 97% identical to the amino acids 203 to 736 of SEQ ID NO: 123.

3. A composition comprising the rAAV according to claim 1 and a physiologically compatible carrier.

4. A recombinant adeno-associated virus (rAAV) having an AAV capsid comprising vp1 proteins, vp2 proteins, and vp3 proteins, wherein the vp1 proteins have the amino acid sequence of amino acids 1 to 736 of SEQ ID NO: 123 (AAV9 capsid protein) with 1 to 37 amino acid modifications and wherein the AAV capsid has packaged therein a minigene having AAV inverted terminal repeats and a heterologous gene operably linked to regulatory sequences which direct expression of the heterologous gene in a host cell.

5. The rAAV according to claim 4 , wherein the AAV vp1 capsid protein has an amino acid sequence which is at least 97% identical to the amino acids 1 to 736 of SEQ ID NO: 123.

6. The rAAV according to claim 4 , wherein the AAV vp1 capsid protein has an amino acid sequence which is at least 99% identical to the amino acids 1 to 736 of SEQ ID NO: 123.

7. The rAAV according to claim 4 , wherein the AAV vp3 capsid protein has an amino acid sequence which is at least 97% identical to the amino acids 203 to 736 of SEQ ID NO: 123.

8. The rAAV according to claim 4 , wherein the AAV vp3 capsid protein has an amino acid sequence which is at least 99% identical to the amino acids 203 to 736 of SEQ ID NO: 123.

9. A recombinant adeno-associated virus (rAAV) having an AAV capsid comprising vp1 proteins, vp2 proteins, and vp3 proteins, wherein the vp2 proteins have the amino acid sequence of amino acids 138 to 736 of SEQ ID NO: 123 (AAV9 capsid protein) with 1 to 29 amino acid modifications, and wherein the AAV capsid has packaged therein a minigene having AAV inverted terminal repeats and a heterologous gene operably linked to regulatory sequences which direct expression of the heterologous gene in a host cell.

10. The rAAV according to claim 9 , wherein the AAV vp2 capsid protein has an amino acid sequence which is at least 97% identical to the amino acids 138 to 736 of SEQ ID NO: 123.

11. The rAAV according to claim 9 , wherein the AAV vp2 capsid protein has an amino acid sequence which is at least 99% identical to the amino acids 138 to 736 of SEQ ID NO: 123.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF THE FOURTH ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 046710 FRAME 0229. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 7, 2019
From: WILSON, JAMES M.; GAO, GUANGPING; ALVIRA, MAURICIO R.; VANDENBERGHE, LUK H.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 049985/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2018
From: WILSON, JAMES M.; GAO, GUANGPING; ALVIRA, MAURICIO R.; VANDENBERGHE, LUC H.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 046710/0229 →
Continuity (6)
Continuation 15227418 · Aug 3, 2016
Continuation 13023918 · Feb 9, 2011
Continuation 10573600
Provisional Application 60566546 · Apr 29, 2004
Provisional Application 60508226 · Sep 30, 2003
Related Publication 20190015527A1 · Jan 17, 2019
Cited By (8)
US 12,296,025 US 12,419,969 US 12,467,046 US 12,577,588 US 12,600,989 US 12,612,647 US 12,630,842 US 12,644,101